News

NORD Issues Statement on Approval of 21st Century Cures Initiative and Introduction of OPEN Act


 

References

NORD President and CEO Peter L. Saltonstall praised the House Energy and Commerce Committee for its recent unanimous approval of the 21st Century Cures Initiative, which includes broad-ranging provisions to enhance the development and delivery of medical treatments. Mr. Saltonstall also noted the introduction in the Senate of the OPEN Act, which encourages the repurposing of approved drugs for the treatment of life-threatening rare diseases. Read the NORD statement.

Recommended Reading

Leukocytoclastic vasculitis incidence underestimated
MDedge Dermatology
International Pemphigus and Pemphigoid Foundation to be Honored at NORD Gala
MDedge Dermatology
NORD to honor NIH Director and others at Portraits of Courage Celebration
MDedge Dermatology
NORD urges Congress to support development of treatments for rare pediatric diseases
MDedge Dermatology
International Pemphigus and Pemphigoid Foundation to be honored at NORD gala
MDedge Dermatology
VIDEO: Lymphadenectomies don’t boost survival in melanoma with SLN micrometastases
MDedge Dermatology
Nonprofits launch web campaign to raise awareness about scleroderma
MDedge Dermatology
VIDEO: Do pathogenic intestinal bacteria drive scleroderma GI symptoms?
MDedge Dermatology
First gut microbiota alterations described in systemic sclerosis patients
MDedge Dermatology
NORD, EURORDIS, and Rare Disease Organizations in 30 Nations Announce an International Rare Diseases Alliance (copy 1)
MDedge Dermatology